Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Medicenna Therapeutics Corp. has reported promising results from its Phase 1/2 ABILITY-1 study, showcasing significant single-agent activity of MDNA11 in patients with advanced solid tumors. The study also highlights a favorable safety profile when MDNA11 is combined with KEYTRUDA, indicating potential for enhanced cancer treatment options. These developments are promising for investors watching the biotech sector.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
